Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era - Université de Lorraine
Article Dans Une Revue Advances in Therapy Année : 2022

Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era

Résumé

No abstract available

Domaines

Sciences du Vivant [q-bio]

Benjamin GROSJEAN  : Connectez-vous pour contacter le contributeur

https://hal.univ-lorraine.fr/hal-04168336

Soumis le : vendredi 21 juillet 2023-14:48:57

Dernière modification le : jeudi 31 octobre 2024-11:36:03

Consulter le texte intégral

Dates et versions

hal-04168336 , version 1 (21-07-2023)

Identifiants

Citer

Stefan Schreiber, Shomron Ben-Horin, Rieke Alten, René Westhovens, Laurent Peyrin‐biroulet, et al.. Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. Advances in Therapy, 2022, 39 (5), pp.2281. ⟨10.1007/s12325-022-02082-9⟩. ⟨hal-04168336⟩

Exporter

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

UNIV-LORRAINE NGERE-UL BMS-UL
15 Consultations
0 Téléchargements

Altmetric

Partager

More